Duffy, J. (2015, September 30). Role of molecular markers in guiding therapy in cancer [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved February 26, 2024, from https://hstalks.com/bs/3129/.
Export Citation (RIS)
Published on September 30, 2015
Prof. Joe Duffy has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Please wait while the transcript is being prepared...
Hello.My name is Professor Joe Duffy.I work at St. Vincent's
University Hospitaland University College, Dublin.The title of my presentation is
the Role of Molecular Markersin Guiding Therapy in Cancer.
List some of the
questions that emergefollowing a diagnosis of cancer.The first question is who to treat?In other words, which
patients, followingsurgical removal of a
primary tumor, should receiveadditional or adjuvant treatment?If the decision is to treat,
the next question is how to treat?In other words, what is the
most appropriate treatmentfor a given patient?Of a major concern to the
patient, is will the treatmentcaused major toxicity?And a fourth issue
is how to determineif treatment is effective?In other words, how to know
if the treatment is working?The aim of this
lecture is to discusshow molecular markers can help
address these four questions,
starting with who to treat.Patients with aggressive
or life-threatening tumorsgenerally receive
adjuvant treatment.On the other hand, patients
with indolent tumorsmay be able to avoid having
to receive adjuvant treatmentand thus be spared from the
toxicity and costs of these drugs.The distinction between
aggressive and indolent tumorsis aided by prognostic
markers or prognostic factors.
So why do we need
prognostic markers?Well, prognostic markers
help avoid undertreatmentof aggressive tumors and
overtreatment of indolent tumors.